 |
InterPro: IPR001864 Trypanothione reductase
Protein matches
|
UniProtKB Matches: 24 proteins |
|
Accession
|
IPR001864 Trypnth_redctse |
Type
|
Family |
Signatures
|
|
InterPro Relationships
|
|
Contains
|
IPR001327 Pyridine nucleotide-disulphide oxidoreductase, NAD-binding region
IPR004099 Pyridine nucleotide-disulphide oxidoreductase, dimerisation
IPR012999 Pyridine nucleotide-disulphide oxidoreductase, class I, active site
IPR013027 FAD-dependent pyridine nucleotide-disulphide oxidoreductase
IPR016156 FAD/NAD-linked reductase, dimerisation
|
GO Term annotation
|
|
Process
|
GO:0055114 oxidation reduction
|
|
Function
|
GO:0015036 disulfide oxidoreductase activity
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
Trypanothione reductase from Leishmania, and African and South American trypanosomes, has been purified and characterised [1]. The enzymes have similar physical, mechanistic and kinetic properties, and are members of the flavoprotein disulphide oxidoreductase family. Trypanothione is the parasite analogue of glutathione, hence this enzyme is equivalent to glutathione reductase. It catalyses the reaction:
NADPH + trypanothione = NADP(+) + reduced trypanothione
Trypanothione reductase shows pronounced specificty for its disulphide substrates, trypanothione disulphide or glutathionylspermidine disulphide. The 3D structure of the enzyme has been determined and its mode of substrate binding revealed in detail [2], offering hope for the design of drugs to combat Chagas disease. The structure belongs to the alpha+beta class, i.e. with mainly anti-parallel beta-sheets separated by alpha and beta regions. It contains an alpha-beta sandwich characteristic of FAD/NAD-linked reductases and a C-terminal dimerisation domain.
|
Structural links
|
|
Database links
|
|
Additional Reading
|
|
Zhang Y, Bond CS, Bailey S, Cunningham ML, Fairlamb AH, Hunter WN.
The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution.
Protein Sci. 5 1996 52-61
[PubMed: 8771196]
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=8771196
|
|
Saravanamuthu A, Vickers TJ, Bond CS, Peterson MR, Hunter WN, Fairlamb AH.
Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design.
J. Biol. Chem. 279 2004 29493-500
[PubMed: 15102853]
http://dx.doi.org/10.1074/jbc.M403187200
|
|
Bond CS, Zhang Y, Berriman M, Cunningham ML, Fairlamb AH, Hunter WN.
Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors.
Structure 7 1999 81-9
[PubMed: 10368274]
http://dx.doi.org/10.1016/S0969-2126(99)80011-2
|
|
Bailey S, Fairlamb AH, Hunter WN.
Structure of trypanothione reductase from Crithidia fasciculata at 2.6 A resolution; enzyme-NADP interactions at 2.8 A resolution.
Acta Crystallogr. D Biol. Crystallogr. 50 1994 139-54
[PubMed: 15299452]
http://dx.doi.org/10.1107/S0907444993011898
|
|
|
InterPro 23.1
|